Evaluation of the effect of stromal vascular fraction (SVF) on the treatment of generalized plaque psoriasis

Evaluation of the effect of autologous adipose derived stem cells stromal vascular fraction (SVF) on the treatment of generalized plaque psoriasis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150601022512N3

Enrollment

Registered

2019-03-09

Start date

2019-03-11

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized plaque psoriasis. Psoriasis vulgaris

Interventions

Intervention group: Patients are subjected to venous infusion of autologous adipose derived stem cells stromal vascular fraction (SVF) twice at intervals of one month. Each time, after an aspiration o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Body Mass Index value of 18 to 25 generalized plaque psoriasis based on Psoriasis Area and Severity Index (PASI) of more than 10 or based on more than 10% body involvement

Exclusion criteria

Exclusion criteria: coagulation disorder use of anticoagulation medicines heart, lung, kidney, liver diseases and malignancy contraindication for liposuction active infections including HIV, HCV, HBV, HTLV1 absence of mental health

Design outcomes

Primary

Measure	Time frame
Evaluation of interleukin serum level of 10. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Venous blood sample.;Measurement of severity of psoriasis. Timepoint: Before and after treatment. Method of measurement: Psoriasis Area and Severity Index (PASI) questionnaire.;Quality-of-life Index of skin patients. Timepoint: Before and after treatment. Method of measurement: Dermatology Life Quality Index questionnaire.;Evaluation of interleukin serum level of 17. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Venous blood sample.;Evaluation of tumor necrosis factor alpha. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Laboratory method.;Evaluation of Interferon-Gamma serum level. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Laboratory method.	—

Measure

Time frame

Evaluation of interleukin serum level of 10. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Venous blood sample.;Measurement of severity of psoriasis. Timepoint: Before and after treatment. Method of measurement: Psoriasis Area and Severity Index (PASI) questionnaire.;Quality-of-life Index of skin patients. Timepoint: Before and after treatment. Method of measurement: Dermatology Life Quality Index questionnaire.;Evaluation of interleukin serum level of 17. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Venous blood sample.;Evaluation of tumor necrosis factor alpha. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Laboratory method.;Evaluation of Interferon-Gamma serum level. Timepoint: Before commencement of SVF injection and at 1, 3 and 6 months after the injection. Method of measurement: Laboratory method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaezeh Taghavi

Mashhad University of Medical Sciences

taghavif941@mums.ac.ir+98 51 3801 2493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026